AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11458304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genders (overall comparison)
Number of subjects: 239
Study 9626225 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 intravenously (i.v.) over 30 minutes daily for 5 days repeated every 21 days (arm A)
Number of subjects: 63
Study 9626225 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.75 mg/m2 as a 24-hour infusion once a week for 4 weeks repeated every 6 weeks (arm B)
Number of subjects: 63
Study 7949497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal GH with 4% DDPC
Number of subjects: 16
Study 7949497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal GH with 8% DDPC
Number of subjects: 16
Study 7949497 — intervention group
Group type: COMPARATOR
Intervention: Nasal GH with 0% DDPC
Number of subjects: 16
Study 7949497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal GH with 16% DDPC
Number of subjects: 16
Study 3278765 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bolus dressing
Number of subjects: 40
Study 3278765 — intervention group
Group type: COMPARATOR
Intervention: Quilting sutures and no dressing
Number of subjects: 40
Study 31435692 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combined with motor training (rTMS‐MT)
Number of subjects: 19
Study 31435692 — intervention group
Group type: COMPARATOR
Intervention: Motor training (MT)
Number of subjects: 19
Study 28654562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 28
Study 28654562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26899941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB)
Number of subjects: 176
Study 26899941 — intervention group
Group type: COMPARATOR
Intervention: Observation (no axillary surgical staging)
Number of subjects: 176
Study 25231109 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (exercise group; n = 14)
Number of subjects: 33
Study 25231109 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 33
Study 22817607 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention consisting of six individual guidance sessions with a physiotherapist and a home-based exercise program.
Number of subjects: 100
Study 22817607 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (control group).
Number of subjects: 100
Study 19638824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooper 12-Minute run/walk test (CT12)
Number of subjects: 45
Study 19638824 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption ((.)Vo2max)
Number of subjects: 45
Study 19638824 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise time
Number of subjects: 45
Study 17765608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-modulated pacing (DDDR)
Number of subjects: 872
Study 17765608 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacing (DDD)
Number of subjects: 872
Study 14980942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE) with intrathecal hyperbaric 0.5% bupivacaine 5 mg and fentanyl 10 microg, followed by 0.9% saline 6.0 mL through the epidural catheter 5 min thereafter
Number of subjects: 62
Study 14980942 — intervention group
Group type: COMPARATOR
Intervention: Single-shot spinal anesthesia with hyperbaric 0.5% bupivacaine 9 mg and fentanyl 10 microg
Number of subjects: 62
Study 12127831 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G‐F 20 (AC+H)
Number of subjects: 255
Study 12127831 — intervention group
Group type: COMPARATOR
Intervention: Appropriate care without hylan G‐F 20 (AC)
Number of subjects: 255
Study 9619732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ara-C/daunorubicin (HDara-C/DNR) after idarubicin induction
Number of subjects: 27
Study 9619732 — intervention group
Group type: COMPARATOR
Intervention: High-dose ara-C/daunorubicin (HDara-C/DNR) after daunorubicin induction
Number of subjects: 27
Study 7633693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal immunotherapy (LNIT) with Parietaria
Number of subjects: 20
Study 7633693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2675377 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg x 2/day for two weeks, then 10 mg x 2/day for two months)
Number of subjects: 113
Study 2675377 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/day for two months)
Number of subjects: 113
Study 2675377 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 113
Study 2675377 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 113
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (5 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (10 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (45 mg)
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg) morning ingestion
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg) morning ingestion
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg) morning ingestion
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (10 mg) morning ingestion
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg) choice response time test
Number of subjects: 0
Study 359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg) choice response time test
Number of subjects: 0
Study 30339211 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation e-cigs (white)
Number of subjects: 3364
Study 30339211 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation e-cigs
Number of subjects: 3364
Study 30339211 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation e-cigs
Number of subjects: 3364
Study 31552710 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD + INT (n=13; 12 supervised 60-min INT bouts of 3 min at 90% and 50% HRpeak)
Number of subjects: 25
Study 31552710 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD + INT
Number of subjects: 25
Study 31552710 — intervention group
Group type: COMPARATOR
Intervention: LCD (n=12)
Number of subjects: 25
Study 31552710 — intervention group
Group type: COMPARATOR
Intervention: LCD
Number of subjects: 25
Study 28193455 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube with subglottic secretion drainage (ETT‐SD) and cuff pressure monitorization
Number of subjects: 133
Study 28193455 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal tube (control)
Number of subjects: 133
Study 25833972 — intervention group
Group type: EXPERIMENTAL
Intervention: WinFood (WF)
Number of subjects: 419
Study 25833972 — intervention group
Group type: EXPERIMENTAL
Intervention: WinFood-Lite (WF-L)
Number of subjects: 419
Study 25833972 — intervention group
Group type: COMPARATOR
Intervention: CSB+
Number of subjects: 419
Study 25833972 — intervention group
Group type: COMPARATOR
Intervention: CSB++
Number of subjects: 419
Study 23332309 — intervention group
Group type: COMPARATOR
Intervention: Externally unsupported thin wall knitted polyester (P-non-EXS)
Number of subjects: 265
Study 23332309 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally supported thin wall knitted polyester (P-EXS)
Number of subjects: 265
Study 21844392 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime
Number of subjects: 0
Study 21844392 — intervention group
Group type: COMPARATOR
Intervention: rAd5 prime
Number of subjects: 0
Study 21844392 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Number of subjects: 0
Study 19288533 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil capsule 0.9 mL, thrice daily for 4 weeks
Number of subjects: 100
Study 19288533 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium capsule 50 mg, thrice daily for 4 weeks
Number of subjects: 100
Study 16881913 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, pre- and post-natal lactation consultant (LC) intervention
Number of subjects: 382
Study 16881913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 382
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure reduction
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibition
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor antagonism
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockade
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive multidisciplinary patient education within a renal unit
Number of subjects: 1000000
Study 14748914 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific interventions for atherosclerotic renal artery stenosis, diabetic nephropathy, lupus nephritis, and certain forms of primary glomerulonephritis
Number of subjects: 1000000
Study 11395029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified fat spread (25 g/day providing 2.5 g of plant sterols)
Number of subjects: 62
Study 11395029 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 62
Study 9232297 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using meperidine with background infusion (group Pi)
Number of subjects: 40
Study 9232297 — intervention group
Group type: COMPARATOR
Intervention: PCEA using meperidine without background infusion (group Po)
Number of subjects: 40
Study 8125422 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor), started after the first day but within 72 hours of onset of chest pain
Number of subjects: 204
Study 8125422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 3021006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate/low fiber dietary advice
Number of subjects: 135
Study 3021006 — intervention group
Group type: COMPARATOR
Intervention: Higher carbohydrate/higher fiber regimen
Number of subjects: 135
Study 29736497 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse (0.2%; CHX; positive control)
Number of subjects: 24
Study 29736497 — intervention group
Group type: EXPERIMENTAL
Intervention: ASF toothpaste
Number of subjects: 24
Study 29736497 — intervention group
Group type: EXPERIMENTAL
Intervention: HTP toothpaste
Number of subjects: 24
Study 29736497 — intervention group
Group type: EXPERIMENTAL
Intervention: STP toothpaste
Number of subjects: 24
Study 27206612 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus clomiphene citrate
Number of subjects: 116
Study 27206612 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 116
Study 25392618 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci single-console
Number of subjects: 40
Study 25392618 — intervention group
Group type: COMPARATOR
Intervention: da Vinci dual-console
Number of subjects: 40
Study 22768459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg)
Number of subjects: 22
Study 22768459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose water for injection, 5 cc/kg)
Number of subjects: 22
Study 16510384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Symphytum product Traumaplant (10% active ingredient)
Number of subjects: 215
Study 16510384 — intervention group
Group type: COMPARATOR
Intervention: 1% reference product (2.5 g of fresh comfrey herb in 100 g of cream)
Number of subjects: 215
Study 12168688 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten and casein-free diet
Number of subjects: 20
Study 12168688 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 20
Study 10540994 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic reconstruction using a periosteal flap
Number of subjects: 10
Study 10540994 — intervention group
Group type: COMPARATOR
Intervention: Evans tenodesis
Number of subjects: 10
Study 8848206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (up to 60 mg/d)
Number of subjects: 7
Study 8848206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2081142 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 120 mg (V120 SR) given twice daily (bid)
Number of subjects: 15
Study 2081142 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg (V240 SR) given once daily (od)
Number of subjects: 15
Study 2081142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 X 0.025 mg/24 hours - 0.075 mg/24 hours, increased if necessary at intervals of two weeks)
Number of subjects: 37
Study 35414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 35414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 37
Study 29499583 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Index (AFI)
Number of subjects: 0
Study 29499583 — intervention group
Group type: COMPARATOR
Intervention: Single Deepest Vertical Pocket (SDP)
Number of subjects: 0
Study 27449226 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth reinforcement
Number of subjects: 84
Study 27449226 — intervention group
Group type: COMPARATOR
Intervention: mHealth monitoring
Number of subjects: 84
Study 26635090 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (prOVag®) with metronidazole
Number of subjects: 578
Study 26635090 — intervention group
Group type: COMPARATOR
Intervention: Placebo with metronidazole
Number of subjects: 578
Study 24075772 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg/d)
Number of subjects: 23
Study 24075772 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (25 mg)
Number of subjects: 23
Study 24075772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21440672 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl once daily for 4 weeks
Number of subjects: 368
Study 21440672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 19146605 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Arctium lappa fruit extract-containing formulation for 12 weeks
Number of subjects: 0
Study 19146605 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Arctium lappa fruit extract-containing formulation for 4 weeks
Number of subjects: 0
Study 19146605 — intervention group
Group type: COMPARATOR
Intervention: In vitro studies with pure Arctiin
Number of subjects: 0
Study 16567815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling (biannually)
Number of subjects: 1062
Study 16567815 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1062
Study 14531561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres
Number of subjects: 0
Study 10750765 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 80
Study 10750765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 80
Study 10750765 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 80
Study 8935813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg/day
Number of subjects: 205
Study 8935813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 8935813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (various doses)
Number of subjects: 205
Study 1411095 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 40
Study 1411095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3159639 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine alone (Group I)
Number of subjects: 114
Study 3159639 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine + HBIG at birth (Group II)
Number of subjects: 114
Study 3159639 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine + HBIG at birth and again at one month (Group III)
Number of subjects: 114
Study 3159639 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 114
Study 30518444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory level III device with end tidal carbon dioxide (etCO2)
Number of subjects: 28
Study 30518444 — intervention group
Group type: COMPARATOR
Intervention: Level I polysomnography (PSG)
Number of subjects: 28
Study 26903575 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus SIRT
Number of subjects: 530
Study 26903575 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 (control)
Number of subjects: 530
Study 24799541 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 532
Study 24799541 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 532
Study 22734376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-rehabilitation group (routine rehabilitation therapy combined with electroacupuncture therapy)
Number of subjects: 70
Study 22734376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-rehabilitation group
Number of subjects: 70
Study 22734376 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 70
Study 20348364 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of Change measure
Number of subjects: 293
Study 20348364 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Balance measure
Number of subjects: 293
Study 20348364 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy measure
Number of subjects: 293
Study 18458247 — intervention group
Group type: EXPERIMENTAL
Intervention: Five annual screening examinations
Number of subjects: 1520
Study 16380690 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 22
Study 16380690 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study 12058428 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (5 mcg.kg‐1.min‐1) administered after coronary artery anastomosis (A 1 group: 11 cases)
Number of subjects: 41
Study 12058428 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (5 mcg.kg‐1.min‐1) administered after induction of anesthesia (A 2 group: 13 cases)
Number of subjects: 41
Study 12058428 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-amrinone group: 17 cases)
Number of subjects: 41
Study 10326147 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 150 mg/day
Number of subjects: 504
Study 10326147 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 504
Study 8603632 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) at doses of 1,200, 2,400, 3,000, or 3,600 mg/day (n = 2-4 per group)
Number of subjects: 18
Study 8603632 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 18
Study 8603632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1936112 — intervention group
Group type: EXPERIMENTAL
Intervention: 54Fe-labelled iron preparation (150 mg Fe2+ daily)
Number of subjects: 18
Study 1936112 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available iron preparation (160 mg Fe2+ daily)
Number of subjects: 18
Study 1936112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 18
Study 7011299 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg
Number of subjects: 30
Study 7011299 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg + ephedrine hydrochloride 25 mg
Number of subjects: 30
Study 7011299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31720795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 380
Study 30540490 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face (FtF) communication
Number of subjects: 0
Study 30540490 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) communication
Number of subjects: 0
Study 30540490 — intervention group
Group type: COMPARATOR
Intervention: Online Text-Based (OTB) communication
Number of subjects: 0
Study 28514613 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 62
Study 28514613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25612789 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge strategy (EDS: <72 h, followed by outpatient lifestyle interventions)
Number of subjects: 100